Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective

Efforts to reduce non-urgent hospital attendances during the COVID-19 pandemic have been the focus of much attention from healthcare professionals worldwide. In Ireland, due to funding constraints omalizumab is only available for hospital-based administration. Fifty-eight patients with chronic spont...

Descripción completa

Detalles Bibliográficos
Autores principales: King, Catherine, Cox, Fionnuala, Sloan, Anne, McCrea, Patricia, Edgar, J.David, Conlon, Niall
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452509/
https://www.ncbi.nlm.nih.gov/pubmed/34567347
http://dx.doi.org/10.1016/j.waojou.2021.100587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452509/
https://www.ncbi.nlm.nih.gov/pubmed/34567347
http://dx.doi.org/10.1016/j.waojou.2021.100587

Ejemplares similares